IL262713A - Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases - Google Patents
Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseasesInfo
- Publication number
- IL262713A IL262713A IL262713A IL26271318A IL262713A IL 262713 A IL262713 A IL 262713A IL 262713 A IL262713 A IL 262713A IL 26271318 A IL26271318 A IL 26271318A IL 262713 A IL262713 A IL 262713A
- Authority
- IL
- Israel
- Prior art keywords
- cannabidiol
- reducing
- autoimmune diseases
- treating inflammatory
- steroid dose
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title 1
- 229950011318 cannabidiol Drugs 0.000 title 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/143,694 US9889100B2 (en) | 2013-05-02 | 2016-05-02 | Cannabidiol for treatment of severe and refractory graft-versus-host disease |
| PCT/IL2017/050483 WO2017191630A1 (en) | 2016-05-02 | 2017-05-01 | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL262713A true IL262713A (en) | 2018-12-31 |
| IL262713B1 IL262713B1 (en) | 2024-03-01 |
| IL262713B2 IL262713B2 (en) | 2024-07-01 |
Family
ID=60203614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL262713A IL262713B2 (en) | 2016-05-02 | 2017-05-01 | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3452046A4 (en) |
| KR (1) | KR102537990B1 (en) |
| CN (2) | CN109414443A (en) |
| AU (1) | AU2017260873B2 (en) |
| CA (1) | CA3022900A1 (en) |
| IL (1) | IL262713B2 (en) |
| WO (1) | WO2017191630A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3156487A1 (en) | 2019-10-03 | 2021-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomal cannabinoids and uses thereof |
| IL293808A (en) * | 2019-12-13 | 2022-08-01 | Buzzelet Development And Technologies Ltd | Compositions and methods for treatment of inflammation with steroids and a modulator |
| CA3171890A1 (en) * | 2020-02-19 | 2021-08-26 | DR. MERCHANT, Shreema | Compositions and therapeutic uses of cannabidiol |
| CA3191800A1 (en) * | 2020-09-06 | 2022-03-10 | Sheila LANGIER | Composition comprising cannabinoids, and/or terpens, and methods of using same |
| CN113398104B (en) * | 2021-07-14 | 2022-04-08 | 北京森宏健康科技有限公司 | Use of cannabidiol in the treatment of bilirubin encephalopathy |
| WO2023058016A1 (en) * | 2021-10-04 | 2023-04-13 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Non-steroidal anti-inflammatory drugs and cannabinoids and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0009200A (en) * | 1999-03-22 | 2001-12-26 | Immugen Pharmaceuticals Inc | Compounds and compositions for the treatment of diseases associated with immune dysfunction |
| US20070060638A1 (en) * | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
| US8242178B2 (en) * | 2007-06-18 | 2012-08-14 | University Of South Carolina | Use of cannabidiol in the treatment of autoimmune hepatitis |
| EP2309858A4 (en) * | 2008-07-31 | 2011-09-14 | Dekel Pharmaceuticals Ltd | Compositions and methods for treating inflammatory disorders |
-
2017
- 2017-05-01 CN CN201780040985.2A patent/CN109414443A/en active Pending
- 2017-05-01 CN CN202311190299.7A patent/CN117017998A/en active Pending
- 2017-05-01 CA CA3022900A patent/CA3022900A1/en active Pending
- 2017-05-01 IL IL262713A patent/IL262713B2/en unknown
- 2017-05-01 AU AU2017260873A patent/AU2017260873B2/en active Active
- 2017-05-01 EP EP17792603.7A patent/EP3452046A4/en active Pending
- 2017-05-01 WO PCT/IL2017/050483 patent/WO2017191630A1/en unknown
- 2017-05-01 KR KR1020187034907A patent/KR102537990B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017260873B2 (en) | 2023-03-02 |
| AU2017260873A1 (en) | 2018-11-29 |
| CA3022900A1 (en) | 2017-11-09 |
| CN117017998A (en) | 2023-11-10 |
| EP3452046A4 (en) | 2020-02-19 |
| EP3452046A1 (en) | 2019-03-13 |
| CN109414443A (en) | 2019-03-01 |
| KR102537990B1 (en) | 2023-05-30 |
| IL262713B2 (en) | 2024-07-01 |
| KR20190016952A (en) | 2019-02-19 |
| IL262713B1 (en) | 2024-03-01 |
| WO2017191630A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275600A (en) | Exosomes for immuno-oncology and anti-inflammatory therapy | |
| IL262713A (en) | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases | |
| IL253701A0 (en) | Therapeutic agent for bile duct cancer | |
| IL260383B (en) | Low dose therapeutic treatment | |
| RS59446B1 (en) | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases | |
| IL251985A0 (en) | A method and device for external urinary incontinence treatment for women | |
| PT3419699T (en) | Dose control system for injectable-drug delivery devices and associated methods of use | |
| EP3634442A4 (en) | Methods for treating and preventing diseases | |
| HUE050603T2 (en) | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis | |
| ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
| PL3151812T3 (en) | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic | |
| IL253026A0 (en) | Calcitonin analogues for treating diseases and disorders | |
| HUE056154T2 (en) | Pectin compositions for preventing and treating inflammatory diseases | |
| EP3222281A4 (en) | Preventive and therapeutic agent for celiac disease | |
| IL263203A (en) | Combination therapy comprising a polyunsaturated ketone and a corticosteroid | |
| EP3356561A4 (en) | Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation | |
| GB201500555D0 (en) | Method and device for the treatment of diseases | |
| IL250244B (en) | Preventing and treating inflammatory skin diseases | |
| IL252203A0 (en) | Treatment of skin atrophy with a combination of triiodothyroacetic acid (triac) and dehydroepiandrosterone (dhea) | |
| GB201415812D0 (en) | Electronic cigarette and system of dose control | |
| GB201414706D0 (en) | Calcitonin mimetics for treating diseases and disorders |